deferiprone and triazoles

deferiprone has been researched along with triazoles in 132 studies

Research

Studies (132)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	43 (32.58)	29.6817
2010's	81 (61.36)	24.3611
2020's	8 (6.06)	2.80

Authors

Authors	Studies
Humbert, H; Mangoni, P; Marfil, F; Maurer, G; Rouan, MC; Séchaud, R	1
Nathan, DG	1
Kontoghiorghes, GJ	7
Cabantchik, ZI; Hershko, CM; Konijn, AM; Link, GM	1
Porter, JB	2
Hershko, C	2
Cabantchik, ZI; El, RB; Glickstein, H; Shvartsman, M	1
El Beshlawy, A	1
Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ	1
Kolnagou, A; Kontoghiorghes, GJ	2
Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G	1
Fischer, R; Harmatz, P; Nielsen, P; Piga, A	1
Greenberg, PL	1
Neufeld, EJ	1
Aguilar, MI; Gonzalez, I; Moats, R; Nelson, M; Nick, H; Otto-Duessel, M; Shimada, H; Wood, JC	1
Barton, JC	1
Rose, C	1
Maggio, A	1
Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Lescoat, G; Nick, H; Pasdeloup, N	1
Bernhardt, PV	1
Hajjizadeh, M; Heli, H; Jabbari, A; Karimian, K; Moosavi-Movahedi, AA; Shafiee, A	1
Goldberg, SL	1
Berdoukas, V; Modell, B	1
Bring, P; Ford, JA; Partovi, N; Yoshida, EM	1
Kwiatkowski, JL	1
Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S	1
Aguilar, M; Moats, R; Nelson, MD; Nick, H; Otto-Duessel, M; Wood, JC	1
Edwards, J; Ibrahim, AS; Spellberg, B	1
Cappellini, MD; Porter, JB; Taher, AT; Vichinsky, EP	1
Bagust, A; Boland, A; Chu, P; Dickson, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Kirkham, J; McLeod, C; Modell, B; Olujohungbe, A; Telfer, P; Walley, T	1
Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A	1
Kim, DM; Neupane, GP	1
Cappellini, MD; Pattoneri, P	1
Ahmad, F; Amani, M; Babaahmadi, A; Divsalar, A; Farzami, B; Hakimelahi, GH; Kamarie, M; Karimian, K; Moosavi-Movahedi, AA; Mousavy, SJ; Poursasan, N; Riazi, GH; Saboury, AA; Shafiee, A; Tsai, FY	1
Chang, JS; Chiou, SS; Hsiao, CC; Hung, GY; Peng, CT; Wang, LY; Wang, SC; Wu, KH	1
Chan, GC; Chan, S; Ha, SY; Ho, PL	1
Efstathiou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Michaelides, Y	1
Fibach, E; Prus, E	1
Brissot, P; Cannie, I; Gaboriau, F; Gouffier, L; Leray, AM; Lescoat, G; Loréal, O; Ropert, M; Troadec, MB	1
Telfer, P	1
Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V	1
Fausel, CA	1
Balocco, M; Carrara, P; Forni, GL; Pinto, V	1
Kolnagou, A; Kontoghiorghes, GJ; Petrikkos, G; Skiada, A	1
Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K	1
Inati, A; Khoriaty, E; Musallam, KM; Taher, AT	1
Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G	1
Porter, JB; Shah, FT	1
Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS	1
Crichton, RR; Della Corte, L; Dexter, DT; Freinbichler, W; Statton, SA; Tipton, KF; Ward, RJ; Weinberger, P; Whitmore, C	1
Balooch, FD; Golbafan, MR; Iranmanesh, M; Jamilaldin Fatemi, S; Saljooghi, AS	1
Mullié, C; Sonnet, P	1
Berdoukas, V; Coates, T; Farmaki, K; Wood, JC	1
Chao, NJ; Kanda, J; Kawabata, H	1
Christoulas, D; Terpos, E; Voskaridou, E	1
Chaiyakunapruk, N; Luangasanatip, N; Upakdee, N; Wong, P	1
Aloj, G; Bonifazi, F; Cappellini, MD; Cassarà, F; Ceci, A; Cianciulli, P; Filosa, A; Fucharoen, S; Gluud, C; Grady, RW; Harmatz, P; Iacono, A; Kattamis, A; Maggio, A; Porter, JB; Prossomariti, L; Vitrano, A; Wood, J	1
Musallam, KM; Taher, AT	1
El-Beshlawy, A; Evangeli, M; Porter, JB	1
Saljooghi, AS	1
Kohli, S; Saxena, R; Verma, IC	1
Pankaew, T; Torcharus, K	1
Fernandes, JL	1
Karakukcu, C; Karakukcu, M; Ozdemir, MA; Patiroglu, T; Tang, PH; Torun, YA; Unal, E	1
Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ	1
Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L	1
Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S	1
Cappellini, MD; Hoffbrand, AV; Taher, A	1
Agapidou, A; Economou, M; Efthimia, V; Neokleous, N; Perifanis, V; Teli, A; Vetsiou, E	1
Aylak, F; Canatan, D; Erdoğan, E; Ormeci, AR; Vural, H	1
Ruivard, M	1
Balocco, M; Forni, GL; Frassoni, F; Musallam, KM; Musso, M; Piaggio, G; Podestà, M; Pozzi, S; Rosa, A	1
Kurtoglu, E; Uygun, V	1
Al Rawas, A; Bashir, W; Pathare, A; Tony, S; Wali, Y; Zachariah, M	1
Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G	1
Dahooee Balooch, F; Ebrahimpour, R; Fatemi, SJ; Iranmanesh, M	1
Brittenham, GM; Olivieri, NF	1
Bedford, MR; Ford, SJ; Horniblow, RD; Iqbal, TH; Tselepis, C	1
Balooch, FD; Fatemi, SJ; Golbafan, MR; Iranmanesh, M	1
Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J	1
Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ	1
Bina, P; Cossa, S; Danjou, F; Defraia, E; Dessì, C; Foschini, ML; Galanello, R; Leoni, G; Matta, G; Morittu, M; Origa, R	1
de Witte, T	1
Chung, J; Jang, JH; Jo, DY; Kim, HJ; Lee, JH; Lee, JW; Yoon, SS	1
Balooch, FD; Fatemi, SJ; Iranmanesh, M	1
Huang, L; Jiang, H; Xia, S; Zhang, W	1
Economou, M; Garypidou, V; Gombakis, N; Kargioti, A; Neokleous, N; Papachristou, F; Teli, A; Theodoridou, S; Vakalopoulou, S; Vlachaki, E; Vyzantiadis, TA	1
Merkel, DG; Nagler, A	1
Chan, GC; Cheuk, DK; Chiang, AK; Dee, CM; Ha, SY	1
Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V	1
Aaseth, J; Andersen, O; Cao, Y; Skaug, MA	1
Genc, GE; Gumuslu, S; Kupesiz, A; Kurtoglu, E; Ozturk, Z	1
Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y	1
Attri, SV; Bansal, D; Bhatia, P; Marwaha, RK; Totadri, S; Trehan, A	1
Garbowski, M; Porter, J; Vlachodimitropoulou Koumoutsea, E	1
Genc, GE; Gumuslu, S; Kupesiz, A; Ozturk, Z	1
Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA	1
Chen, V; Clemons, KV; Cohen, K; Ferreira, JA; Haagensen, JA; Hsu, JL; Martinez, M; Nazik, H; Penner, JC; Spormann, AM; Stevens, DA	1
El Rassi, F; Saliba, AN; Taher, AT	1
Aygener, N; Eyigor, H; Kurtoglu, E; Osma, U; Yilmaz, MD	1
Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S	1
Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E	1
Kontoghiorghe, CN; Kontoghiorghes, GJ	1
Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V	1
Gomber, S; Jain, P; Narang, M; Sharma, S	1
Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S	1
Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F	1
Bentley, A; Caruso, V; Cuccia, L; D'Ascola, DG; Filosa, A; Frizziero, L; Hanif, A; Meloni, A; Pepe, A; Putti, MC; Rossi, G; Spasiano, A	1
Chandra, J; Dhingra, B; Jain, R; Mahto, D; Parakh, N; Sharma, S	1
Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK	1
Leitch, HA; Wong, SA	1
Aydogdu, S; Bayramoglu, Z; Dursun, M; Karagenc, AO; Karakas, Z; Karaman, S; Tugcu, D; Yilmaz, Y	1
Sivaramakrishnan, G; Sridharan, K	1
Doree, C; Estcourt, LJ; Fisher, SA; Fortin, PM; Hopewell, S; Madgwick, KV; Trivella, M	1
Sari, TT; Wahidiyat, PA; Yosia, M	1
Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ	1
Bintoro, SUY; Qatrunnada, H; Wahyuni, S	1
Borella, E; Della Pasqua, O; Magni, P; Oosterholt, S	1
Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E	1
Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ	1
Bova, C; Bruzzese, A; Capodanno, I; Filippelli, G; Gentile, M; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E	1
Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y	1
Aydinok, Y	1

Reviews

47 review(s) available for deferiprone and triazoles

Article	Year
Clinical research: a tale of two studies. Transactions of the American Clinical and Climatological Association, 2003, Volume: 114 Topics: Benzoates; Biomedical Research; Cooperative Behavior; Deferasirox; Deferiprone; Drug Design; Drug Industry; Humans; Iron Chelating Agents; Pyridones; Thalassemia; Triazoles	2003
Monitoring and treatment of iron overload: state of the art and new approaches. Seminars in hematology, 2005, Volume: 42, Issue:2 Suppl 1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemosiderin; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Magnetics; Pyridones; Triazoles	2005
Treating iron overload: the state of the art. Seminars in hematology, 2005, Volume: 42, Issue:2 Suppl 1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Survival Analysis; Triazoles	2005
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Current medicinal chemistry, 2005, Volume: 12, Issue:23 Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles	2005
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators. Current medicinal chemistry, 2005, Volume: 12, Issue:23 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles	2005
Objectives and mechanism of iron chelation therapy. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles	2005
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Pyridones; Retrospective Studies; Thalassemia; Triazoles	2005
Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Journal of the National Comprehensive Cancer Network : JNCCN, 2006, Volume: 4, Issue:1 Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles	2006
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood, 2006, May-01, Volume: 107, Issue:9 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis; Deferasirox; Deferiprone; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles	2006
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles	2006
Chelation therapy for iron overload. Current gastroenterology reports, 2007, Volume: 9, Issue:1 Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles	2007
Light and shadows in the iron chelation treatment of haematological diseases. British journal of haematology, 2007, Volume: 138, Issue:4 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Triazoles	2007
Coordination chemistry and biology of chelators for the treatment of iron overload disorders. Dalton transactions (Cambridge, England : 2003), 2007, Aug-14, Issue:30 Topics: Benzoates; Chemistry, Pharmaceutical; Crystallography, X-Ray; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Humans; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Triazoles	2007
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leukemia research, 2007, Volume: 31 Suppl 3 Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Survival Rate; Transfusion Reaction; Treatment Outcome; Triazoles	2007
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles	2008
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy, 2008, Volume: 28, Issue:3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Diet; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Mutation; Phlebotomy; Pyridones; Triazoles	2008
Oral iron chelators. Pediatric clinics of North America, 2008, Volume: 55, Issue:2 Topics: Administration, Oral; Benzoates; Chelating Agents; Child; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Overload; Pyridones; Siderophores; Triazoles	2008
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Current opinion in infectious diseases, 2008, Volume: 21, Issue:6 Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbial Viability; Mucorales; Mucormycosis; Pyridones; Triazoles	2008
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2009, Volume: 13, Issue:1 Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical; Transfusion Reaction; Treatment Outcome; Triazoles	2009
Oral iron chelators. Annual review of medicine, 2009, Volume: 60 Topics: Administration, Oral; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles	2009
Update on survival in thalassemia major. Hemoglobin, 2009, Volume: 33 Suppl 1 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Follow-Up Studies; Humans; Iron Chelating Agents; Pyridones; Survival Rate; Treatment Outcome; Triazoles	2009
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert opinion on drug safety, 2010, Volume: 9, Issue:4 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Interactions; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Pyridones; Triazoles	2010
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2010
Iron overload and allogeneic hematopoietic stem-cell transplantation. Expert review of hematology, 2011, Volume: 4, Issue:1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Transplantation, Homologous; Triazoles	2011
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood cells, molecules & diseases, 2011, Oct-15, Volume: 47, Issue:3 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; MEDLINE; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Treatment Outcome; Triazoles; Ventricular Function	2011
Iron chelation therapy for transfusional iron overload: a swift evolution. Hemoglobin, 2011, Volume: 35, Issue:5-6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles	2011
Past, present & future scenario of thalassaemic care & control in India. The Indian journal of medical research, 2011, Volume: 134 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Female; Genetic Carrier Screening; Humans; India; Male; Preimplantation Diagnosis; Prenatal Diagnosis; Pyridones; Thalassemia; Triazoles	2011
Iron chelation therapy in the management of transfusion-related cardiac iron overload. Transfusion, 2012, Volume: 52, Issue:10 Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Forecasting; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Practice Guidelines as Topic; Prospective Studies; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left	2012
Iron mobilization using chelation and phlebotomy. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2012, Volume: 26, Issue:2-3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Thalassemia; Triazoles	2012
Management of transfusion-related iron overload in patients with myelodysplastic syndromes. Clinical journal of oncology nursing, 2012, Volume: 16 Suppl Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles	2012
[Iron chelating therapy in adults: How and when ?]. La Revue de medecine interne, 2013, Volume: 34, Issue:1 Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles	2013
Management of the thalassemias. Cold Spring Harbor perspectives in medicine, 2013, Jun-01, Volume: 3, Issue:6 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pancreas; Pituitary Gland, Anterior; Pyridones; Thalassemia; Triazoles	2013
Iron chelation in the treatment of cancer: a new role for deferasirox? Journal of clinical pharmacology, 2013, Volume: 53, Issue:9 Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Neoplasms; Pyridones; Triazoles	2013
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles	2013
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PloS one, 2013, Volume: 8, Issue:12 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Stroke Volume; Thalassemia; Treatment Outcome; Triazoles	2013
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes. Expert review of anticancer therapy, 2014, Volume: 14, Issue:7 Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles	2014
Chelation in metal intoxication--Principles and paradigms. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2015, Volume: 31 Topics: Administration, Oral; Antidotes; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Heavy Metal Poisoning; Humans; Penicillamine; Poisoning; Pyridones; Succimer; Triazoles; Trientine; Unithiol	2015
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Expert review of hematology, 2016, Volume: 9, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pregnancy; Pyridones; Triazoles	2016
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug design, development and therapy, 2016, Volume: 10 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles	2016
Deferasirox for managing iron overload in people with thalassaemia. The Cochrane database of systematic reviews, 2017, 08-15, Volume: 8 Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Patient Satisfaction; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Triazoles	2017
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:6 Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles	2018
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. The Cochrane database of systematic reviews, 2018, 05-08, Volume: 5 Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Patient Compliance; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Triazoles	2018
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report. Acta medica Indonesiana, 2018, Volume: 50, Issue:2 Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; Indonesia; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Pyridones; Thalassemia; Triazoles	2018
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2023, Volume: 30, Issue:1 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles	2023
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease. Frontiers in bioscience (Elite edition), 2022, 07-12, Volume: 14, Issue:3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Risk Assessment; Thalassemia; Triazoles	2022
Iron chelation therapy. European journal of haematology, 2023, Volume: 110, Issue:5 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles	2023
Combination chelation therapy. Annals of the New York Academy of Sciences, 2023, Volume: 1529, Issue:1 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Quality of Life; Triazoles	2023

Trials

4 trial(s) available for deferiprone and triazoles

Article	Year
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. European journal of haematology, 2009, Volume: 82, Issue:6 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Treatment Outcome; Triazoles; Young Adult	2009
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Annals of hematology, 2012, Volume: 91, Issue:9 Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Follow-Up Studies; Heart; Heart Failure; Humans; Iron Chelating Agents; Male; Myocardium; Patient Compliance; Prospective Studies; Pyridones; Stroke Volume; Triazoles; Young Adult	2012
The effects of chelators on zinc levels in patients with thalassemia major. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2013, Volume: 27, Issue:2 Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Demography; Female; Humans; Iron Chelating Agents; Male; Pyridones; Triazoles; Young Adult; Zinc	2013
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European journal of haematology, 2015, Volume: 95, Issue:5 Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Severity of Illness Index; Triazoles	2015

Other Studies

81 other study(ies) available for deferiprone and triazoles

Article	Year
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. Journal of chromatography. B, Biomedical sciences and applications, 2001, May-05, Volume: 755, Issue:1-2 Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine; Drug Stability; Humans; Hydrogen-Ion Concentration; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temperature; Thalassemia; Triazoles	2001
Do we need more iron-chelating drugs? Lancet (London, England), 2003, Aug-09, Volume: 362, Issue:9382 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2003
Iron chelation therapy. Current hematology reports, 2005, Volume: 4, Issue:2 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Isoniazid; Pyridones; Pyridoxal; Survival; Triazoles	2005
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood, 2005, Nov-01, Volume: 106, Issue:9 Topics: Animals; Benzoates; Catalysis; Cell Line; Cell Survival; Cells; Cytosol; Deferasirox; Deferiprone; Deferoxamine; Endosomes; Humans; Iron; Iron Chelating Agents; Mice; Microscopy, Fluorescence; Mitochondria; Pyridones; Time Factors; Triazoles	2005
The Egyptian experience with oral iron chelators. Hematology (Amsterdam, Netherlands), 2005, Volume: 10 Suppl 1 Topics: Benzoates; Deferasirox; Deferiprone; Egypt; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles	2005
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Translational research : the journal of laboratory and clinical medicine, 2006, Volume: 148, Issue:5 Topics: Animals; Benzoates; Deferasirox; Deferiprone; Disease Models, Animal; Female; Gerbillinae; Heart; Iron; Iron Chelating Agents; Iron Overload; Liver; Organ Size; Pyridones; Triazoles	2006
[Post transfusionnal iron overload]. La Revue du praticien, 2006, Dec-15, Volume: 56, Issue:19 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Pyridones; Randomized Controlled Trials as Topic; Triazoles	2006
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell proliferation, 2007, Volume: 40, Issue:5 Topics: Animals; Apoptosis; Base Sequence; Benzoates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deferasirox; Deferiprone; DNA Primers; DNA Replication; Humans; Iron Chelating Agents; Liver Neoplasms; Liver Neoplasms, Experimental; Polyamines; Pyridones; Rats; Triazoles	2007
Electrocatalytic oxidation and determination of deferasirox and deferiprone on a nickel oxyhydroxide-modified electrode. Analytical biochemistry, 2008, Feb-15, Volume: 373, Issue:2 Topics: Benzoates; Deferasirox; Deferiprone; Electrochemistry; Ion-Selective Electrodes; Iron Chelating Agents; Microscopy, Electron, Scanning; Nickel; Oxidation-Reduction; Pyridones; Triazoles	2008
Transfusion-dependent thalassaemia: a new era. The Medical journal of Australia, 2008, Jan-21, Volume: 188, Issue:2 Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium; Patient Compliance; Pyridones; Siderophores; Thalassemia; Triazoles	2008
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, Volume: 93, Issue:5 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Deferiprone; Deferoxamine; Hematology; Humans; Iron Chelating Agents; Iron Overload; Liver; Practice Guidelines as Topic; Pyridones; Siderophores; Triazoles	2008
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart. Magnetic resonance in medicine, 2008, Volume: 60, Issue:1 Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Gerbillinae; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Siderophores; Tissue Distribution; Triazoles	2008
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Expert opinion on drug safety, 2008, Volume: 7, Issue:6 Topics: Benzoates; Deferasirox; Deferiprone; Drug Therapy, Combination; Heart; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles	2008
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]. Hemoglobin, 2008, Volume: 32, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Hematologic Diseases; Humans; Iron Chelating Agents; Pyridones; Risk Assessment; Siderophores; Triazoles	2008
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin, 2008, Volume: 32, Issue:6 Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug Industry; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Truth Disclosure	2008
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion, 2009, Volume: 49, Issue:8 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Overload; Pyridones; Siderophores; Triazoles; Vibrio Infections; Vibrio vulnificus	2009
The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin. Journal of biomolecular structure & dynamics, 2009, Volume: 27, Issue:3 Topics: Benzoates; beta-Thalassemia; Circular Dichroism; Deferasirox; Deferiprone; Hemoglobins; Humans; Iron Chelating Agents; Pyridones; Spectrometry, Fluorescence; Structure-Activity Relationship; Triazoles	2009
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic; Combined Modality Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Guidelines as Topic; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Pyridones; Siderophores; Siderosis; Taiwan; Treatment Outcome; Triazoles	2009
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Negative Bacterial Infections; Humans; Iron Chelating Agents; Iron Overload; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Prevalence; Pyridones; Thalassemia; Triazoles	2009
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles	2009
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells. Acta haematologica, 2010, Volume: 123, Issue:1 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; Ferritins; Flow Cytometry; Humans; In Vitro Techniques; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Phosphatidylserines; Pyridones; Reactive Oxygen Species; Reticulocytes; Triazoles	2010
Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2010, Volume: 23, Issue:2 Topics: Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Deferasirox; Deferiprone; Dose-Response Relationship, Drug; Female; Ferritins; Hepatocytes; Humans; Iron; Iron Chelating Agents; Liver Neoplasms; Molecular Structure; Pyridones; Receptors, Transferrin; Triazoles	2010
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction. Blood reviews, 2009, Volume: 23 Suppl 1 Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Overload; Pyridones; Triazoles	2009
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta haematologica, 2010, Volume: 123, Issue:3 Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; Child; Child, Preschool; Cystatin C; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Early Diagnosis; Female; Humans; Hypercalciuria; Iron Chelating Agents; Kidney Diseases; Kidney Function Tests; Male; Proteinuria; Pyridones; Triazoles; Young Adult	2010
Iron chelation therapy in myelodysplastic syndromes. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, Volume: 67, Issue:7 Suppl 2 Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Quality-Adjusted Life Years; Siderophores; Treatment Outcome; Triazoles	2010
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. American journal of hematology, 2010, Volume: 85, Issue:6 Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Young Adult	2010
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. Hemoglobin, 2010, Volume: 34, Issue:3 Topics: Anti-Infective Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Infections; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles	2010
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. European journal of haematology, 2010, Volume: 85, Issue:4 Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; Deferoxamine; Female; Greece; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Male; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2010
Pathogenesis and management of iron toxicity in thalassemia. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles	2010
Iron chelation therapy for patients with sickle cell disease and iron overload. American journal of hematology, 2010, Volume: 85, Issue:10 Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Erythrocyte Transfusion; Humans; Infusion Pumps; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Male; Pain; Patient Compliance; Pyridones; Sensation Disorders; Social Isolation; Triazoles; Young Adult; Zinc	2010
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica, 2011, Volume: 96, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyridones; Retrospective Studies; Siderophores; Triazoles; Ventricular Function; Young Adult	2011
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:4 Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Egypt; Electrocardiography; Female; Ferritins; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridones; Sex Factors; Siderophores; Siderosis; Triazoles	2010
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:2 Topics: Animals; Benzoates; Brain; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Immunohistochemistry; Injections, Intraventricular; Iron Chelating Agents; Male; Microdialysis; Neuroprotective Agents; Parkinsonian Disorders; Pyridones; Rats; Rats, Sprague-Dawley; Sorbic Acid; Triazoles	2011
Chelation of cadmium by combining deferasirox and deferiprone in rats. Toxicology and industrial health, 2011, Volume: 27, Issue:4 Topics: Animals; Benzoates; Cadmium Compounds; Cadmium Poisoning; Chelation Therapy; Deferasirox; Deferiprone; Drug Combinations; Iron Chelating Agents; Iron Compounds; Male; Pyridones; Rats; Rats, Wistar; Spectrophotometry, Atomic; Triazoles	2011
In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin. Experimental parasitology, 2011, Volume: 128, Issue:1 Topics: Antimalarials; Benzoates; Chloroquine; Deferasirox; Deferiprone; Deferoxamine; Glutathione; Hemeproteins; Hemin; Hydrogen Peroxide; Inhibitory Concentration 50; Iron Chelating Agents; Plasmodium falciparum; Pyridones; Structure-Activity Relationship; Triazoles; Triterpenes; Ursolic Acid	2011
Iron chelation in thalassemia: time to reconsider our comfort zones. Expert review of hematology, 2011, Volume: 4, Issue:1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Pyridones; Survival Analysis; Thalassemia; Triazoles	2011
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. British journal of haematology, 2011, Volume: 154, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles	2011
Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clinical drug investigation, 2011, Volume: 31, Issue:7 Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Markov Chains; Models, Economic; Pyridones; Quality-Adjusted Life Years; Thailand; Triazoles	2011
Challenges of adherence and persistence with iron chelation therapy. International journal of hematology, 2011, Volume: 94, Issue:5 Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Dosage Forms; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Patient Care Team; Patient Compliance; Pyridones; Time Factors; Triazoles	2011
Chelation of aluminum by combining deferasirox and deferiprone in rats. Toxicology and industrial health, 2012, Volume: 28, Issue:8 Topics: Aluminum; Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Iron; Male; Pyridones; Rats; Rats, Wistar; Triazoles	2012
Health-related quality of life in Thai thalassemic children treated with iron chelation. The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:4 Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Emotions; Female; Health Status; Humans; Interpersonal Relations; Iron Chelating Agents; Male; Pyridones; Quality of Life; Severity of Illness Index; Social Support; Thailand; Thalassemia; Triazoles	2011
Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy. Hemoglobin, 2012, Volume: 36, Issue:3 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Male; Pyridones; Treatment Outcome; Triazoles; Ubiquinone; Young Adult	2012
How I treat transfusional iron overload. Blood, 2012, Nov-01, Volume: 120, Issue:18 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles	2012
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Female; Greece; Humans; Hypercalciuria; Hyperuricemia; Iron Chelating Agents; Iron Overload; Male; Nephrolithiasis; Postoperative Complications; Pyridones; Splenectomy; Transfusion Reaction; Triazoles; Young Adult	2013
Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major. Haematologica, 2013, Volume: 98, Issue:4 Topics: Adult; Benzoates; beta-Thalassemia; Blood Cell Count; Chelation Therapy; Colony-Forming Units Assay; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Erythroid Precursor Cells; Female; Ferritins; Flow Cytometry; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Linear Models; Male; Multivariate Analysis; Myeloid Progenitor Cells; Pyridones; Splenectomy; Triazoles; Young Adult	2013
Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology (Amsterdam, Netherlands), 2013, Volume: 18, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Middle Aged; Pyridones; Retrospective Studies; Splenectomy; Triazoles; Young Adult	2013
Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience. Pediatric hematology and oncology, 2013, Volume: 30, Issue:2 Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Female; Ferritins; Humans; Infant; Iron Chelating Agents; Male; Pyridones; Retrospective Studies; Triazoles; Vitamin D Deficiency	2013
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. British journal of haematology, 2013, Volume: 161, Issue:6 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Liver; Male; Pyridones; Software; Triazoles; Young Adult	2013
Chelation of chromium(VI) by combining deferasirox and deferiprone in rats. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2013, Volume: 26, Issue:3 Topics: Animals; Benzoates; Body Weight; Chelating Agents; Chelation Therapy; Chromium; Deferasirox; Deferiprone; Male; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tissue Distribution; Triazoles	2013
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert opinion on drug safety, 2013, Volume: 12, Issue:5 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Marketing; Patient Safety; Pyridones; Thalassemia; Triazoles	2013
Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2013, Volume: 26, Issue:5 Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Disease Models, Animal; Drug Therapy, Combination; Male; Mercury; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tissue Distribution; Triazoles; Volatilization	2013
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leukemia research, 2013, Volume: 37, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles	2013
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Predictive Value of Tests; Pyridones; Risk; ROC Curve; Sampling Studies; Transfusion Reaction; Triazoles; Young Adult	2013
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival? Leukemia research, 2013, Volume: 37, Issue:12 Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles	2013
Korean guideline for iron chelation therapy in transfusion-induced iron overload. Journal of Korean medical science, 2013, Volume: 28, Issue:11 Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Republic of Korea; Transfusion Reaction; Triazoles	2013
Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2014, Volume: 27, Issue:1 Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Lead; Male; Models, Biological; Molecular Structure; Pyridones; Rats; Rats, Wistar; Triazoles	2014
Laboratory investigation of platelet function in patients with thalassaemia. Acta haematologica, 2014, Volume: 132, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Platelets; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyridones; Triazoles; Young Adult	2014
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia. British journal of haematology, 2014, Volume: 167, Issue:3 Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Tubules; Male; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles; Water-Electrolyte Imbalance; Young Adult	2014
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin, 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult	2014
Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress. Free radical research, 2015, Volume: 49, Issue:3 Topics: Adolescent; Adult; Antioxidants; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Glutathione Transferase; Humans; Iron Chelating Agents; Male; Oxidative Stress; Oxidoreductases; Peroxiredoxins; Pyridones; Thioredoxin Reductase 1; Thioredoxins; Triazoles; Young Adult	2015
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Pediatric blood & cancer, 2015, Volume: 62, Issue:9 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Eruptions; Drug Therapy, Combination; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Joint Diseases; Male; Prospective Studies; Proteinuria; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2015
Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization. British journal of haematology, 2015, Volume: 170, Issue:6 Topics: Benzoates; Cell Line; Deferasirox; Deferiprone; Deferoxamine; Drug Synergism; Humans; Intracellular Space; Iron; Iron Chelating Agents; Pyridones; Triazoles	2015
Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators. Biological trace element research, 2016, Volume: 170, Issue:1 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Male; Minerals; Pyridones; Triazoles; Young Adult	2016
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. Infectious disorders drug targets, 2015, Volume: 15, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones; Triazoles	2015
Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10 Topics: Antifungal Agents; Aspergillus fumigatus; Benzoates; Biofilms; Chlorides; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Iron; Iron Chelating Agents; Microbial Sensitivity Tests; Plankton; Pyridones; Spores, Fungal; Tetrazolium Salts; Triazoles	2015
Sensorineural hearing loss in β-thalassemia patients treated with iron chelation. Ear, nose, & throat journal, 2015, Volume: 94, Issue:12 Topics: Adolescent; Adult; Audiometry, Pure-Tone; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Hearing Loss, Sensorineural; Humans; Iron Chelating Agents; Male; Middle Aged; Pyridones; Triazoles; Young Adult	2015
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Experimental physiology, 2016, Volume: 101, Issue:4 Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles	2016
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? International journal of hematology, 2016, Volume: 103, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Female; Fetus; Humans; Infant, Newborn; Iron Chelating Agents; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pyridones; Triazoles	2016
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Annals of hematology, 2016, Volume: 95, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles	2016
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Indian pediatrics, 2016, Volume: 53, Issue:3 Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Pyridones; Thalassemia; Transfusion Reaction; Triazoles	2016
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats. PloS one, 2016, Volume: 11, Issue:7 Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; Deferoxamine; Drug Combinations; Drug Synergism; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Malondialdehyde; Mitochondria; Pyridones; Rats; Rats, Wistar; Triazoles; Ventricular Function, Left	2016
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; Deferiprone; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Proteinuria; Pyridones; Transfusion Reaction; Triazoles; Young Adult	2017
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective. Clinical drug investigation, 2017, Volume: 37, Issue:5 Topics: Benzoates; beta-Thalassemia; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Health Care Costs; Humans; Iron Chelating Agents; Italy; Pyridones; Treatment Outcome; Triazoles	2017
Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:3 Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; India; Iron Chelating Agents; Kidney Function Tests; Liver Function Tests; Male; Prospective Studies; Pyridones; Tertiary Care Centers; Triazoles	2017
Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Frontiers in bioscience (Landmark edition), 2018, 01-01, Volume: 23, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2018
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit? Leukemia research, 2018, Volume: 64 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyridones; Retrospective Studies; Triazoles	2018
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. La Radiologia medica, 2018, Volume: 123, Issue:8 Topics: Adolescent; Adult; Benzoates; Blood Component Transfusion; Chelation Therapy; Child; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyridones; Retrospective Studies; Thalassemia; Treatment Outcome; Triazoles; Turkey	2018
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran. Hemoglobin, 2021, Volume: 45, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc	2021
Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya. Journal of basic and clinical physiology and pharmacology, 2021, Jun-25, Volume: 32, Issue:4 Topics: Adult; Benzoates; beta-Thalassemia; Costs and Cost Analysis; Deferasirox; Deferiprone; Drug Utilization; Ferritins; Hospitals, General; Humans; Iron Chelating Agents; Pharmaceutical Preparations; Retrospective Studies; Triazoles	2021
Characterisation of individual ferritin response in patients receiving chelation therapy. British journal of clinical pharmacology, 2022, Volume: 88, Issue:8 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Pyridones; Triazoles	2022
Nephrolithiasis in two patients on iron chelation therapy: A case report. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2023, Volume: 62, Issue:3 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Nephrolithiasis; Triazoles	2023